5-Amino-1MQ vs SLU-PP-332
Two novel small-molecule 'metabolism in a pill' compounds with elegant mouse mechanisms and the exact same problem — zero human trials of any kind.
Short answer
Neither 5-Amino-1MQ nor SLU-PP-332 has much human evidence; both are graded preclinical / minimal, so trials cannot say which works better. 5-Amino-1MQ is the one sold for fat loss and metabolism, while SLU-PP-332 targets metabolic health. Both are sold gray-market as research chemicals.
5-Amino-1MQ
An NNMT inhibitor that reverses obesity in mice by sparing the NAD+ pool; the mechanism is plausible, but the human evidence is nonexistent.
Full 5-Amino-1MQ evidence reviewSLU-PP-332
A synthetic ERR agonist that reproduces exercise-like gene-expression changes in mice — a genuinely novel mechanism with zero human data of any kind; everything sold under this name is unregulated research material.
Full SLU-PP-332 evidence review5-Amino-1MQ vs SLU-PP-332: head to head
- FDA status / approved use
5-Amino-1MQ
Sold as a research chemical; not an approved medicineSLU-PP-332
Not a drug or dietary supplement; not approved anywhere; sold online as a research chemical- Marketed for
5-Amino-1MQ
Fat loss, metabolismSLU-PP-332
'Exercise mimetic', metabolic health- Outcome areas
5-Amino-1MQ
Weight loss / appetite; Mitochondrial / cellular energySLU-PP-332
Exercise performance / endurance; Blood sugar / insulin sensitivity; Mitochondrial / cellular energy- Evidence grade
5-Amino-1MQ
Preclinical / minimalSLU-PP-332
Preclinical / minimal- How it works
5-Amino-1MQ
Small molecule that inhibits NNMT, an enzyme that wastes NAD+ building blocksSLU-PP-332
Activates estrogen-related receptors ERRα, ERRβ and ERRγ to mimic endurance-training adaptations- Route and dosing
5-Amino-1MQ
Not establishedSLU-PP-332
Not established- Headline human result
5-Amino-1MQ
Not establishedSLU-PP-332
Not established- Strongest evidence
5-Amino-1MQ
Neelakantan, Biochem Pharmacol 2018. Little or no controlled human outcome data for the marketed use5-Amino-1MQ evidence reviewPubMed 29155147SLU-PP-332
ERR agonist mouse exercise mimicry, Nat Commun 2023. Little or no controlled human outcome data for the marketed useSLU-PP-332 evidence reviewPubMed 36988910- Key safety signal
5-Amino-1MQ
No human safety data, no human dosing and no human pharmacokineticsSLU-PP-332
No human safety, dosing or long-term data of any kind- How it is obtained
5-Amino-1MQ
Sold gray-market as a research chemical; no approved or legitimately compounded human productSLU-PP-332
Sold gray-market as a research chemical; no approved human product
| 5-Amino-1MQ | SLU-PP-332 | |
|---|---|---|
| FDA status / approved use | Sold as a research chemical; not an approved medicine | Not a drug or dietary supplement; not approved anywhere; sold online as a research chemical |
| Marketed for | Fat loss, metabolism | 'Exercise mimetic', metabolic health |
| Outcome areas | Weight loss / appetite; Mitochondrial / cellular energy | Exercise performance / endurance; Blood sugar / insulin sensitivity; Mitochondrial / cellular energy |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Small molecule that inhibits NNMT, an enzyme that wastes NAD+ building blocks | Activates estrogen-related receptors ERRα, ERRβ and ERRγ to mimic endurance-training adaptations |
| Route and dosing | Not established | Not established |
| Headline human result | Not established | Not established |
| Strongest evidence | Neelakantan, Biochem Pharmacol 2018. Little or no controlled human outcome data for the marketed use5-Amino-1MQ evidence reviewPubMed 29155147 | ERR agonist mouse exercise mimicry, Nat Commun 2023. Little or no controlled human outcome data for the marketed useSLU-PP-332 evidence reviewPubMed 36988910 |
| Key safety signal | No human safety data, no human dosing and no human pharmacokinetics | No human safety, dosing or long-term data of any kind |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
5-Amino-1MQ is an NNMT inhibitor that reverses obesity in mice by sparing the NAD+ pool — a plausible, well-characterized mechanism with genuinely nonexistent human evidence. SLU-PP-332 works differently, as a synthetic ERR agonist that reproduces exercise-like gene-expression changes in mice — equally novel, equally untested in people. Both are early-stage research chemicals sold as finished supplements years ahead of any human data.
5-Amino-1MQ fits if
The fat-loss/NNMT mechanism specifically is the interest, understanding this is unregulated research material with no human safety data.
SLU-PP-332 fits if
The 'exercise mimetic' mechanism specifically is the interest — same caveat: no human trials of any kind exist.
5-Amino-1MQ vs SLU-PP-332: common questions
- Is either 5-Amino-1MQ or SLU-PP-332 FDA-approved?
- No. 5-Amino-1MQ is sold as a research chemical; not an approved medicine. SLU-PP-332 is not a drug or dietary supplement; not approved anywhere; sold online as a research chemical.
- Which has stronger human evidence, 5-Amino-1MQ or SLU-PP-332?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for 5-Amino-1MQ is Neelakantan, Biochem Pharmacol 2018; for SLU-PP-332, it is ERR agonist mouse exercise mimicry, Nat Commun 2023.
- What are the main safety concerns with 5-Amino-1MQ and SLU-PP-332?
- 5-Amino-1MQ has no human safety data, no human dosing and no human pharmacokinetics. SLU-PP-332 has no human safety, dosing or long-term data of any kind.
Key studies behind each
5-Amino-1MQ
- Neelakantan H, Vance V, Wetzel MD, et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. PubMed 29155147
- Babula JJ, Bui D, Stevenson HL, et al. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. PubMed 39161060
- Awosemo O, Neelakantan H, Watowich S, et al. (2021). Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. PubMed 34304009
- Neelakantan H, Brightwell CR, Graber TG, et al. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. PubMed 30753815
SLU-PP-332
- Billon C, Sitaula S, Banerjee S, et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. PubMed 36988910
- Billon C, Schoepke E, Avdagic A, et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. PubMed 37739806
- Xu W, Billon C, Li H, et al. (2024). Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. PubMed 37961903
The full evidence reviews
- 5-Amino-1MQ: an elegant mechanism with no human trials
An NNMT inhibitor that reverses obesity in mice by sparing the NAD+ pool — without reducing food intake. The mechanism is plausible; the human evidence is nonexistent.
Updated August 2026
- SLU-PP-332: the “exercise mimetic” that lives entirely in mice
A synthetic pan-agonist of the ERRα/β/γ receptors switches on an endurance-training program — in rodents and cell culture. A straight read of the preclinical evidence, and why there is no human story yet.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm 5-Amino-1MQ availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: PeptiRNK HealthSunlightTMatesRxPepsDirectRxSaludable